Beyer Pat 4

What Happened
Pat Beyer, a director of Bioventus Inc. (BVS), had 32,282 restricted stock units (RSUs) vest and be converted into Class A common shares on June 2, 2026 (exercise/conversion reported at $0.00). The Form 4 shows both an "acquired" and a "disposed" derivative entry for the 32,282 units, indicating the derivative RSU instruments were converted into underlying shares rather than sold in the market. On June 3, 2026 Beyer was granted 25,146 new RSUs (reported as an award at $0.00) that are contingent rights to receive shares subject to future vesting.

Key Details

• Transaction dates/prices: June 2, 2026 — conversion of 32,282 RSUs into shares @ $0.00; June 3, 2026 — grant of 25,146 RSUs @ $0.00. Total cash exchanged: $0.
• Footnotes: F1 — each RSU = contingent right to one share; F2 — the RSUs that converted vested on June 2, 2026; F3 — the 25,146 RSUs vest on the earlier of the first annual meeting after grant or the first anniversary of grant, subject to continued board service.
• Shares owned after transaction: not specified in the filing.
• Filing/timeliness: Form 4 filed June 4, 2026 for transactions on June 2–3, 2026 — appears timely.

Context
This activity reflects compensation-related equity (vesting and a new RSU grant), not an open-market purchase or sale. The conversion increased Beyer’s issued shares without any cash payment; the new RSUs are subject to future vesting and service conditions. For retail investors, compensation-related conversions/grants are routine and do not directly signal the insider buying or selling stock in the open market.